News releases - Merck.com
WEBSeptember 11, 2024. Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males. September 07, 2024. Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial.
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
WEBFeb 1, 2024 · Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel Assets Into Phase 3 in 2023. Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration Agreements With Daiichi Sankyo and Kelun-Biotech in 2023. Full-Year 2024 Financial Outlook.
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB3 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Merck to Acquire EyeBio - Merck.com
WEBMay 29, 2024 · Merck to acquire EyeBio for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments for a potential value of $3 billion.
Merck & Co., Inc. (MRK) Latest Stock News & Headlines
WEBGet the latest Merck & Co., Inc. (MRK) stock news and headlines to help you in your trading and investing decisions.
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
WEB4 days ago · Merck acquired global co-development and co-commercialization rights to patritumab deruxtecan/MK-1022 and two other ADCs, raludotatug deruxtecan/MK-5909 and ifinatamab deruxtecan/MK-2400 from ...
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For …
WEB3 days ago · (RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
WEBMar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. WINREVAIR logo (Graphic: Merck & Co., Inc.)
Merck’s fourth-quarter results top estimates, fueled by key cancer ...
WEBFeb 1, 2024 · Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts’ expectations, powered by strong growth in cancer and vaccine products.
Merck & Co Inc (MRK) Stock Price & News - Google Finance
WEBGet the latest Merck & Co Inc (MRK) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Skip to content